NanoSanguis

Oxygen-carrier therapeutics · Organ preservation, ischemia

Overview

Perfluorocarbon-based artificial oxygen carriers and enzyme therapeutics for organ preservation and oxygen delivery.

What they do

NanoSanguis is a Polish biotech, originating from doctoral research at the Warsaw University of Technology and associated with the NanoGroup ecosystem, that develops perfluorocarbon (PFC) based artificial oxygen carriers and enzyme therapeutics. Its technology uses biologically inert PFC nanoparticles that mimic red blood cells, transporting oxygen and removing carbon dioxide, with applications in organ preservation and oxygen delivery during ischemia.

Lead program & status

The lead program is the NanOX system, a perfusion fluid plus device designed to keep transplant organs oxygenated under sub- and normothermic machine-perfusion conditions. The company reports that NanOX has, in preclinical work, supported organs after prolonged ischemia (on the order of 30–40 minutes versus only a few minutes for conventional methods), and it has described confirming oxygen and CO2 transport in a pig kidney autotransplantation model with subsequent organ regeneration. These are reported preclinical findings; the platform is in development rather than approved clinical use. Research literature continues to explore PFC nanoemulsions for simultaneous oxygen and antioxidant delivery during machine-perfusion organ preservation.

Why it matters

Donor organs deteriorate rapidly without oxygenation, limiting transplant logistics and viability. By extending tolerable ischemic time and supporting organ regeneration during perfusion, NanoSanguis's PFC carriers could widen the donor pool and improve transplant outcomes.

FAQ

What is NanOX?

NanOX is NanoSanguis's perfusion fluid and device system that uses perfluorocarbon nanoparticles to oxygenate organs during machine perfusion, aimed at improving organ preservation before transplantation.

How do perfluorocarbon oxygen carriers work?

Perfluorocarbons are biologically inert fluorinated compounds that can dissolve and release large amounts of oxygen and carbon dioxide, allowing PFC nanoparticles to act as artificial red-blood-cell-like oxygen carriers.

Is the technology approved for clinical use?

As of the latest available information it is in development, with reported preclinical results (including animal organ-perfusion studies) rather than approved clinical use.

Company website / source ↗ Open the interactive map →